Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Combination With FLAG-IDA in Relapsed or Refractory AML
NCT00651781Phase 2Completed
- Sponsor
- Fundación PETHEMA
- Start
- Apr 2008
- Primary completion
- Jan 2013
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in acute myeloid leukemia (AML), sponsored by Fundación PETHEMA. Primary endpoint: Efficacy (Response Rate) at 1 year. Started Apr 2008; status: completed.
02
Drugs
bortezomib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00651781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00651781.